Caitlin Tourje, MD
Pain Medicine · Camarillo, CANPI 1033571872
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.2%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Biotronik NRO, Inc. accounts for 84.2% of it on its own, with 37 other manufacturers making up the rest. 2025 is the largest year on record at $34,151, more than ten times the $99 reported in 2020. Among pain medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 600 payments — averaging $132.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik NRO, Inc.$67K
- Nevro Corp.$4K
- Relievant Medsystems, Inc.$909
- AbbVie$874
- Medtronic$824
- SPR Therapeutics, Inc$820
- plus $5K from 32 others
What the payments were for
- Consulting fees$13,98618%
- Speaking & faculty fees$41,66252%
- Travel & lodging$5,5947%
- Food & beverage$18,49523%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotronik NRO, Inc. | 212 | $67,156 |
| Nevro Corp. | 68 | $3,886 |
| Relievant Medsystems, Inc. | 24 | $909 |
| AbbVie | 43 | $874 |
| Medtronic(2 entities) | 31 | $824 |
| SPR Therapeutics, Inc | 15 | $820 |
| Boston Scientific | 37 | $804 |
| Foundation Fusion Solutions, LLC | 15 | $797 |
| Saluda Medical Americas, Inc. | 11 | $486 |
| Vertex | 13 | $443 |
| Globus Medical | 4 | $331 |
| Painteq LLC | 11 | $304 |
| Collegium Pharmaceutical, Inc. | 20 | $294 |
| IBSA Pharma Inc. | 28 | $235 |
| Scilex Pharmaceuticals Inc. | 14 | $231 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $206 |
| Abbott | 6 | $175 |
| Vertos Medical, Inc. | 1 | $138 |
| Lundbeck LLC | 6 | $134 |
| Nalu Medical, Inc. | 3 | $98 |
| Azurity Pharmaceuticals, Inc. | 3 | $72 |
| Amgen | 3 | $55 |
| Fidia Pharma USA Inc. | 3 | $53 |
| Bioventus LLC | 1 | $48 |
| Lilly USA, LLC | 2 | $45 |
| Curonix LLC | 1 | $41 |
| Almatica Pharma LLC | 2 | $35 |
| MML US, Inc. | 2 | $33 |
| Biodelivery Sciences International, Inc. | 2 | $29 |
| Virtus Pharmaceuticals LLC | 1 | $25 |
| Averitas Pharma Inc. | 1 | $25 |
| Arbor Pharmaceuticals, Inc. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Radius Health, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Tonix Medicines, Inc. | 1 | $15 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prospera$53,924
- BIOTRONIK$8,364
- Intracept$1,804
- Senza$1,118
- Omnia$876
- SPRINT PNS System$289
- Evoke SCS$158
- mild Device Kit$138
- Accurian$136
How this compares
$79,737 in reported general payments places this provider in the 95th percentile of 840 pain medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 36 | $27,925 |
| UbrelvyUbrogepant | 16 | $23,569 |
| QuliptaAtogepant | 21 | $22,537 |
| LicartDiclofenac Epolamine | 26 | $18,025 |
| ZtlidoLidocaine | 40 | $15,131 |
| Buprenorphine | 26 | $7,830 |
| ButransBuprenorphine | 12 | $5,850 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 123 | $2,628 |
| Celecoxib | 11 | $2,120 |
| Pregabalin | 140 | $2,081 |
| Duloxetine Hcl | 175 | $1,974 |
| Gabapentin | 95 | $1,701 |
| Naloxone Hcl | 30 | $1,444 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 42 | $918 |
| Buprenorphine Hcl | 16 | $572 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $874 | $46,10537 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $294 | $27,92536 claims |
| IBSA Pharma Inc.Licart | $235 | $18,02526 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $231 | $15,13140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 840 pain medicine providers in California.
Other pain medicine in Camarillo
- Farid KiaCamarillo$65K
- Jason PopeSanta Rosa$2.1M
- Ramana NaiduLarkspur$1.4M
- Foead GeulaStudio City$1.3M
- Krishnan ChakravarthyTemecula$1.3M
- Kasra AmirdelfanWalnut Creek$783K
- Eric GrigsbyNapa$499K
- Jacqueline WeisbeinNapa$494K
- Gerald SacksSanta Monica$389K
- Samir ShethRoseville$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.